Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

The global prevalence of liver cancer is rapidly rising, mostly as a result of the amplified incidence rates of viral hepatitis, alcohol abuse and obesity in recent decades. Treatment options for liver cancer are remarkably limited with sorafenib being the gold standard for advanced, unresectable hepatocellular carcinoma but offering extremely limited improvement of survival time. The immune system is now recognised as a key regulator of cancer development through its ability to protect against infection and chronic inflammation, which promote cancer development, and eliminate tumour cells when present. However, the tolerogenic nature of the liver means that the immune response to infection, chronic inflammation and tumour cells within the hepatic environment is usually ineffective. Here we review the roles that immune cells and cytokines have in the development of the most common primary liver cancer, hepatocellular carcinoma (HCC). We then examine how the immune system may be subverted throughout the stages of HCC development, particularly with respect to immune inhibitory molecules, also known as immune checkpoints, such as programmed cell death protein-1, programmed cell death 1 ligand 1 and cytotoxic T lymphocyte antigen 4, which have become therapeutic targets. Finally, we assess preclinical and clinical studies where immune checkpoint inhibitors have been used to modify disease during the carcinogenic process. In conclusion, inhibitory molecule-based immunotherapy for HCC is in its infancy and further detailed research in relevant in vivo models is required before its full potential can be realised.

Original languageEnglish
Article number161
Number of pages11
JournalClinical & Translational Immunology
Volume6
DOIs
Publication statusPublished - 10 Nov 2017

Cite this

@article{925b1e492fdc445bbd08c4b7db189500,
title = "Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma",
abstract = "The global prevalence of liver cancer is rapidly rising, mostly as a result of the amplified incidence rates of viral hepatitis, alcohol abuse and obesity in recent decades. Treatment options for liver cancer are remarkably limited with sorafenib being the gold standard for advanced, unresectable hepatocellular carcinoma but offering extremely limited improvement of survival time. The immune system is now recognised as a key regulator of cancer development through its ability to protect against infection and chronic inflammation, which promote cancer development, and eliminate tumour cells when present. However, the tolerogenic nature of the liver means that the immune response to infection, chronic inflammation and tumour cells within the hepatic environment is usually ineffective. Here we review the roles that immune cells and cytokines have in the development of the most common primary liver cancer, hepatocellular carcinoma (HCC). We then examine how the immune system may be subverted throughout the stages of HCC development, particularly with respect to immune inhibitory molecules, also known as immune checkpoints, such as programmed cell death protein-1, programmed cell death 1 ligand 1 and cytotoxic T lymphocyte antigen 4, which have become therapeutic targets. Finally, we assess preclinical and clinical studies where immune checkpoint inhibitors have been used to modify disease during the carcinogenic process. In conclusion, inhibitory molecule-based immunotherapy for HCC is in its infancy and further detailed research in relevant in vivo models is required before its full potential can be realised.",
keywords = "CD8(+) T-CELL, CHRONIC VIRAL-INFECTION, SINUSOIDAL ENDOTHELIAL-CELLS, CHRONIC HEPATITIS-B, C VIRUS-INFECTION, DENDRITIC CELLS, TH17 CELLS, DISEASE PROGRESSION, BLOCKADE SYNERGIZES, ADAPTIVE IMMUNITY",
author = "Elsegood, {Caryn L.} and Tirnitz-Parker, {Janina E. E.} and Olynyk, {John K.} and Yeoh, {George C. T.}",
year = "2017",
month = "11",
day = "10",
doi = "10.1038/cti.2017.47",
language = "English",
volume = "6",
journal = "Clinical & Translational Immunology",
issn = "2050-0068",
publisher = "John Wiley & Sons",

}

TY - JOUR

T1 - Immune checkpoint inhibition

T2 - prospects for prevention and therapy of hepatocellular carcinoma

AU - Elsegood, Caryn L.

AU - Tirnitz-Parker, Janina E. E.

AU - Olynyk, John K.

AU - Yeoh, George C. T.

PY - 2017/11/10

Y1 - 2017/11/10

N2 - The global prevalence of liver cancer is rapidly rising, mostly as a result of the amplified incidence rates of viral hepatitis, alcohol abuse and obesity in recent decades. Treatment options for liver cancer are remarkably limited with sorafenib being the gold standard for advanced, unresectable hepatocellular carcinoma but offering extremely limited improvement of survival time. The immune system is now recognised as a key regulator of cancer development through its ability to protect against infection and chronic inflammation, which promote cancer development, and eliminate tumour cells when present. However, the tolerogenic nature of the liver means that the immune response to infection, chronic inflammation and tumour cells within the hepatic environment is usually ineffective. Here we review the roles that immune cells and cytokines have in the development of the most common primary liver cancer, hepatocellular carcinoma (HCC). We then examine how the immune system may be subverted throughout the stages of HCC development, particularly with respect to immune inhibitory molecules, also known as immune checkpoints, such as programmed cell death protein-1, programmed cell death 1 ligand 1 and cytotoxic T lymphocyte antigen 4, which have become therapeutic targets. Finally, we assess preclinical and clinical studies where immune checkpoint inhibitors have been used to modify disease during the carcinogenic process. In conclusion, inhibitory molecule-based immunotherapy for HCC is in its infancy and further detailed research in relevant in vivo models is required before its full potential can be realised.

AB - The global prevalence of liver cancer is rapidly rising, mostly as a result of the amplified incidence rates of viral hepatitis, alcohol abuse and obesity in recent decades. Treatment options for liver cancer are remarkably limited with sorafenib being the gold standard for advanced, unresectable hepatocellular carcinoma but offering extremely limited improvement of survival time. The immune system is now recognised as a key regulator of cancer development through its ability to protect against infection and chronic inflammation, which promote cancer development, and eliminate tumour cells when present. However, the tolerogenic nature of the liver means that the immune response to infection, chronic inflammation and tumour cells within the hepatic environment is usually ineffective. Here we review the roles that immune cells and cytokines have in the development of the most common primary liver cancer, hepatocellular carcinoma (HCC). We then examine how the immune system may be subverted throughout the stages of HCC development, particularly with respect to immune inhibitory molecules, also known as immune checkpoints, such as programmed cell death protein-1, programmed cell death 1 ligand 1 and cytotoxic T lymphocyte antigen 4, which have become therapeutic targets. Finally, we assess preclinical and clinical studies where immune checkpoint inhibitors have been used to modify disease during the carcinogenic process. In conclusion, inhibitory molecule-based immunotherapy for HCC is in its infancy and further detailed research in relevant in vivo models is required before its full potential can be realised.

KW - CD8(+) T-CELL

KW - CHRONIC VIRAL-INFECTION

KW - SINUSOIDAL ENDOTHELIAL-CELLS

KW - CHRONIC HEPATITIS-B

KW - C VIRUS-INFECTION

KW - DENDRITIC CELLS

KW - TH17 CELLS

KW - DISEASE PROGRESSION

KW - BLOCKADE SYNERGIZES

KW - ADAPTIVE IMMUNITY

U2 - 10.1038/cti.2017.47

DO - 10.1038/cti.2017.47

M3 - Review article

VL - 6

JO - Clinical & Translational Immunology

JF - Clinical & Translational Immunology

SN - 2050-0068

M1 - 161

ER -